Background: Long-term effects of in utero and neonatal antiretroviral (ARV) exposure on cognitive and academic development in HIV-exposed, uninfected school-age children are unknown.
Methods: HIV-exposed, uninfected children, ages 5-13 years, in PHACS SMARTT, a U.S.-based multisite cohort study, completed age-appropriate Wechsler intelligence and academic scales (WPPSI-III, WASI, WIAT-II-A). Associations between cognitive and academic outcomes and in utero ARV exposure by regimen, class, and individual ARVs were evaluated, adjusting for potential confounders. .
Results: Children completing WPPSI-IIIs (n=350) were 49% male, 74% Black, 25% Hispanic; WASI (n=337) and WIAT-II-A (n=415) cohorts were similar. The percentage exposed to combination ARV (cARV) was 84% (WPPSI-III), 64% (WASI), and 67% (WIAT-II-A). Among ARV-exposed children, there were no significant associations between any ARV regimen or class and any cognitive or academic outcome. In addition, in both unadjusted models and after adjustment for caregiver IQ, socio-demographic factors, and maternal health and substance use during pregnancy, no individual ARV drug was associated with significantly lower cognitive or academic scores. Factors typically associated with lower cognitive and academic scores in the general population, such as prematurity, small for gestational age, maternal alcohol use, and lower maternal cognitive status, were also associated with lower scores in this study.
Conclusions: Overall, the safety of prenatal and neonatal ARV use was supported.
(C) 2014 by Lippincott Williams & Wilkins, Inc.